O’Brien Patrick, COO and General Counsel, has demonstrated a consistent pattern of selling shares in Arrowhead Pharmaceuticals (ARWR) over the past three years, with no recorded purchases. According to SEC Form 4 filings, Patrick executed 28 transactions totaling $4.94 million in sales, all concentrated in ARWR. The most recent activity occurred on January 5–6, 2026, with nine sales ranging from $3,128 to $846,874.96, including two high-value transactions exceeding $750,000. This follows a similar trend from January 2025, when Patrick sold shares worth $191,472.60 and $387,066.02, as well as January 2024, when multiple sales—including a $454,216.65 transaction—were reported.
The filings indicate that Patrick’s disposals are clustered in early January each year, suggesting a possible structured selling plan. While some transactions were modest (under $100,000), others were substantial, such as the $755,993.28 and $846,874.96 sales in early 2026. The absence of any buys across all filings reinforces a clear divestment trend. The transactions include both open-market sales (code "S") and gifts (code "G"), though the latter carried no reported value. Given the multiyear consistency and absence of offsetting purchases, the data reflects a sustained reduction in Patrick’s ARWR holdings.
AI-assisted summary